BIO
$269.48
Bio-Rad Laboratories, Inc.
Recent News
Assessing Whether Bio-Rad Laboratories (BIO) Looks Undervalued After Recent Share Price Softness
Assessing Bio-Rad Laboratories after recent performance Bio-Rad Laboratories (BIO) has attracted attention after a mixed stretch of returns, with the stock roughly flat over the past year but showing declines over the past month and past 3 months. See our latest analysis for Bio-Rad Laboratories. At the latest share price of $271.44, Bio-Rad’s short term share price momentum has been fading, while its 1 year total shareholder return of 9.56% contrasts with much weaker 3 and 5 year total...
International Markets and Bio-Rad (BIO): A Deep Dive for Investors
Examine Bio-Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth
Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter and full-year results despite a challenging year marked by geopolitical uncertainty and continued pressure on academic research. The company delivered modest revenue growth and strong free cash […]
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down
BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.
Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price Weakness
If you are wondering whether Bio-Rad Laboratories is starting to look attractively priced after a rough few years, this breakdown will help you put the current share price in context. The stock closed at US$256.56 most recently, with returns of a 14.9% decline over 7 days, 18.2% decline over 30 days, 16.0% decline year to date, 7.4% decline over 1 year, 46.9% decline over 3 years and 59.7% decline over 5 years. These moves have refocused attention on whether the market is being too cautious...